EP. 1: David R. Lally, MD: What Led to the GATHER Trials for Avacincaptad Pegol
A review of the development of complement inhibitors and how the latest GATHER2 data support avacincaptad pegol for the treatment of geographic atrophy.
EP. 2: Which Geographic Atrophy Patients May Benefit from Avacincaptad Pegol
David R. Lally, MD, reviews the duration and patient demographic data of the investigative drug.
EP. 3: A Geographic Atrophy Treatment Breakthrough with David R. Lally, MD
Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.
2 Commerce Drive Cranbury, NJ 08512